NanoViricides is trading at $1.34, up +11.67%, as investors react to the upcoming clinical milestone.
- Shares are extending the prior session’s 14.29% gain.
- NanoViricides said its Phase II NV-387 oral-gummy Ebola trial in the Democratic Republic of Congo is scheduled to begin next week, with first-patient dosing expected shortly, barring outbreak-related delays.
- Biotechnology strength also provides broader support, with XBI up 2.55%.